Drug intelligence / Profile preview

AD-17137

Development stage: Phase 2
Lead developer: Assuta Medical Centers
Modality: Small Molecules
Administration: Topical

Overview

AD-17137 is a small molecule drug developed for the treatment of actinic keratosis, a pre-cancerous skin condition characterized by thick, scaly, or crusty patches on the skin. The compound has been investigated as a topical therapy and reached Phase 2 clinical trials. Its mechanism of action and specific biological targets have not been publicly disclosed. The drug was developed by Assuta Hospital IVF Center and Assuta Medical Centers Ltd., both based in Israel[1][3][4][9].

Targets

TOP1 (DNA Topoisomerase I)

Beyond the preview

Go deeper on AD-17137.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AD-17137.

Explore the full profile